Male bias in medical trials risks women’s lives. But at least the data gap is finally being addressed | Caroline Criado Perez

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has made notable strides by identifying a significant imbalance in clinical trials—nearly twice as many male trials as female ones. While this issue aligns with global trends of women being underrepresented in clinical trials, the UK previously stood out for its lack of efforts to address gender disparity. The MHRA’s pioneering research is encouraging but faces limitations, such as trials often including both sexes without analyzing outcomes by gender and insufficient data on female-specific risks in conditions like cardiovascular disease.